Sentence examples for survival prolongation from inspiring English sources

Data from clinical trials, meta-analyses, databases of large institutions, and cancer registries indicate that chemotherapy can prolong survival, and survival prolongation is associated with the activity of drugs [ 1- 5].

The aims of these treatments include symptomatic control, maintenance of quality of life, tumor shrinkage, prolonging time to progression, and survival prolongation.

Current evidence indicates that new targeted treatments, notably monoclonal antibodies such as ramucirumab and necitumumab, and immunotherapies such as nivolumab and pembrolizumab can provide survival prolongation, although the benefits are still relatively modest.

Understanding of the biochemical consequences of IDH1/2 mutations in oncogenesis and survival prolongation will yield valuable information for rational therapy design: it will tell us which oncogenic processes should be blocked and which "survivalogenic" effects should be retained.

Recently published results from the long-term follow-up of Radiation Therapy Oncology Group (RTOG) trial 9802 demonstrated medically meaningful and statistically significant survival prolongation by adding chemotherapy with procarbazine, lomustine (CCNU), and vincristine after radiotherapy (RT) vs RT alone for "high -risk patients (median 13.3 vs 7.8 years, high -riskio = 0.59, patients).

The management of metastatic breast cancer has evolved considerably in the last 5 6 years and a variety of treatments have been shown to impact on the natural history of this disease over this period, with demonstration of survival prolongation justifiably generating considerable excitement.

Silibinin treatment was associated with a significant prolongation of survival compared with vehicle-treated controls, with a median survival of 34 days versus 25 days, respectively.

However, the prolongation of survival associated with CT is only equivalent to an absolute increase in 1-year survival of 6% (from 40 to 46%; Stewart, 2002).

Although, the prolongation of survival after adjuvant therapy did not reach statistic significance the EORTC trial confirmed that the survival of patients without adjuvant therapy is poor (10 12 months).

In these cases, conversion surgery with simultaneous metastasectomy might have contributed to the prolongation of survival.

Thus specific T cell responses appear to mediate viral-elicited prolongation in survival.